ANGLE Unveils Breakthrough CTC Research at European Cancer Conference

ANGLE plc (AIM:AGL)(OTCQX:ANPCY) marked its presence at the European Association for Cancer Research (EACR) Liquid Biopsies Conference in Lyon, France (November 12-14, 2024) by showcasing two significant posters on circulating tumour cell (CTC) detection and analysis—reinforcing its position as a pioneer in liquid biopsy innovation.

Epitope-Independent CTC Enrichment Reveals Critical Insights in Prostate Cancer

The first presentation focused on the synergy between ANGLE’s flagship Parsortix® system and the Portrait®+ CTC staining kit, demonstrating a standardised approach to capturing and characterising CTCs across multiple phenotypes—including epithelial, mesenchymal, and transitioning cell populations.

Findings from a prostate cancer cohort revealed compelling data: 64% of patients tested positive for CTCs, while CTC clusters (which possess up to 100 times greater metastatic potential) were identified in 67% of CTC-positive samples. Notably, 77% of CTC-positive patients harboured exclusively mesenchymal CTCs, with no patients showing only epithelial variants. These results underscore why epitope-independent enrichment systems like Parsortix are essential—they capture the full spectrum of cancer cells that traditional methods might miss.

The research also illustrated the workflow’s potential for longitudinal patient monitoring, where serial CTC measurements and phenotypic shifts correlate directly with clinical outcomes. Two case studies of metastatic prostate cancer patients demonstrated how CTC dynamics preceded observable changes in patient status, suggesting predictive value for disease surveillance.

Molecular Profiling Advances: Multiplexing dPCR for Deeper Tumour Analysis

The second poster examined enhanced molecular characterisation of CTCs using amplitude-based digital PCR (dPCR) multiplexing in combination with Parsortix enrichment. In metastatic disease settings, where tissue biopsy access is limited or invasive, this approach offers real-time tumour insights and enables monitoring of treatment response and disease progression.

By integrating QIAGEN’s Qiacuity dPCR platform with amplitude-based multiplexing, researchers demonstrated the ability to assess a significantly expanded gene panel from a single Parsortix-enriched CTC sample. This proof-of-concept expands the breadth of genetic markers detectable per sample, providing a more granular view of tumour biology than single-gene approaches.

ANGLE’s Continuing Evolution in CTC Science

Karen Miller, Chief Scientific Officer, noted: “These presentations reinforce ANGLE’s commitment to advancing cellular and molecular CTC characterisation. As multiplexing capabilities mature, so does our ability to decode tumour complexity—insights that are invaluable for targeted drug development and precision oncology research. We are actively expanding our portfolio of Parsortix-based molecular assays to meet the evolving demands of pharmaceutical research partners.”

ANGLE’s Parsortix® PC1 System has earned FDA clearance and is backed by over 100 peer-reviewed publications validating its performance in CTC isolation and downstream analysis—positioning the angle symbol of innovation firmly within the liquid biopsy sector.

Contact Information:

ANGLE plc | Andrew Newland, Chief Executive | +44 (0) 1483 343434

Berenberg (NOMAD & Broker) | Toby Flaux, Ciaran Walsh, Milo Bonser | +44 (0) 20 3207 7800

FTI Consulting | Simon Conway, Ciara Martin, Matthew Ventimiglia (US) | +44 (0) 203 727 1000 / +1 (212) 850 5624